中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2013年
4期
832-833
,共2页
魏礼清%卢忠心%刘水逸%孔晓宇
魏禮清%盧忠心%劉水逸%孔曉宇
위례청%로충심%류수일%공효우
微小RNA181b%癌,肝细胞%实时定量聚合酶链反应
微小RNA181b%癌,肝細胞%實時定量聚閤酶鏈反應
미소RNA181b%암,간세포%실시정량취합매련반응
MicroRNA-181b%Carcinoma,hepatocellular%Real-time quantitative polymerase chain reaction
目的 观察微小RNA181b(miR-181b)在正常胚肝细胞株和肝癌细胞株中的表达,检测该微小RNA在正常肝组织及肝癌组织中的表达,探讨其在肝癌发生发展中的作用和意义.方法 应用实时定量聚合酶链反应(Real-time PCR)法检测miR-181b在1株人正常肝细胞(LO2)及2株人肝癌细胞(HepG2、SMMC7721)中的表达,同时收取35例肝细胞癌手术患者正常组织、癌周组织、癌组织,检测其表达并分析；细胞计数试剂盒(CCK-8)实验及细胞生长曲线检测miR-181b抑制剂对肝癌细胞增殖能力的影响.结果 miR-181b在肝癌细胞(HepG2、SMMC7721)中的表达比正常肝细胞LO2显著增高(0.582±0.032、0.716±0.045、0.255±0.039,P＜O.05),在癌组织中表达显著高于正常组织与癌周组织(0.636±0.038、0.156±0.005、0.167±0.023,P＜0.05),正常组织及癌周组织比较差异无统计学意义(P＞0.05)；miR-181b抑制剂使肝癌细胞增殖能力减弱.结论 miR-181b在肝癌细胞及肝癌组织中的高表达,可能与肝癌发生发展密切相关,抑制miR-181b的表达能够抑制肝癌细胞增殖.
目的 觀察微小RNA181b(miR-181b)在正常胚肝細胞株和肝癌細胞株中的錶達,檢測該微小RNA在正常肝組織及肝癌組織中的錶達,探討其在肝癌髮生髮展中的作用和意義.方法 應用實時定量聚閤酶鏈反應(Real-time PCR)法檢測miR-181b在1株人正常肝細胞(LO2)及2株人肝癌細胞(HepG2、SMMC7721)中的錶達,同時收取35例肝細胞癌手術患者正常組織、癌週組織、癌組織,檢測其錶達併分析；細胞計數試劑盒(CCK-8)實驗及細胞生長麯線檢測miR-181b抑製劑對肝癌細胞增殖能力的影響.結果 miR-181b在肝癌細胞(HepG2、SMMC7721)中的錶達比正常肝細胞LO2顯著增高(0.582±0.032、0.716±0.045、0.255±0.039,P＜O.05),在癌組織中錶達顯著高于正常組織與癌週組織(0.636±0.038、0.156±0.005、0.167±0.023,P＜0.05),正常組織及癌週組織比較差異無統計學意義(P＞0.05)；miR-181b抑製劑使肝癌細胞增殖能力減弱.結論 miR-181b在肝癌細胞及肝癌組織中的高錶達,可能與肝癌髮生髮展密切相關,抑製miR-181b的錶達能夠抑製肝癌細胞增殖.
목적 관찰미소RNA181b(miR-181b)재정상배간세포주화간암세포주중적표체,검측해미소RNA재정상간조직급간암조직중적표체,탐토기재간암발생발전중적작용화의의.방법 응용실시정량취합매련반응(Real-time PCR)법검측miR-181b재1주인정상간세포(LO2)급2주인간암세포(HepG2、SMMC7721)중적표체,동시수취35례간세포암수술환자정상조직、암주조직、암조직,검측기표체병분석；세포계수시제합(CCK-8)실험급세포생장곡선검측miR-181b억제제대간암세포증식능력적영향.결과 miR-181b재간암세포(HepG2、SMMC7721)중적표체비정상간세포LO2현저증고(0.582±0.032、0.716±0.045、0.255±0.039,P＜O.05),재암조직중표체현저고우정상조직여암주조직(0.636±0.038、0.156±0.005、0.167±0.023,P＜0.05),정상조직급암주조직비교차이무통계학의의(P＞0.05)；miR-181b억제제사간암세포증식능력감약.결론 miR-181b재간암세포급간암조직중적고표체,가능여간암발생발전밀절상관,억제miR-181b적표체능구억제간암세포증식.
Objective To explore the role of microRNA-181b (miR-181b) in the pathogenesis of human hepatocellular carcinoma (HCC).Methods We detected the expressions of miR-181 b by using real-time quantitative polymerase chain reaction (Real-time PCR) in LO2 (normal human liver cell line),HepG2 and SMMC7721 (human HCC cell lines),normal liver tissues,para-cancerous tissue and cancerous tissues surgically resected from 35 cases of HCC.Cell Counting Kit-8 (CCK-8) assay and growth curve were used to asses the effect of miR-181b inhibitor on proliferation of HCC cells.Results The expression of miR-181b in HepG2 and SMMC7721 cells was significantly higher than in LO2 cells (0.582 ± 0.032 and 0.716 ±0.045 vs.0.255 ±0.039,P ＜0.05),and that in cancerous tissue was significantly higher than in normal liver tissues and para-cancerous tissues (0.636 ± 0.038 vs.0.156-± 0.005 and 0.167 ± 0.023,P ＜0.05).miR-181b inhibitor could reduce the proliferative ability of HCC cells.Conclusion These results indicate that the high expression of miR-181b is probably involved in HCC pathogenesis.Downregulation of miR-181b expression can inhibit the proliferation of HCC cells.miR-181b may act as a molecular tar-get for HCC diagnosis and targeted therapy.
